Here are JPMorgan’s top drug stock picks into earnings
JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue to sell out of major technology firms. Major market trends in the first half of …
JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue to sell out of major technology firms. Major market trends in the first half of …
The dividend stock club could soon get new members, according to Morgan Stanley. “Committing to a consistent dividend sends a positive signal to the market, conveys management’s confidence in the …
Anti-obesity drugmakers Novo Nordisk and Eli Lilly have a huge lead on their competition, but given the vast and valuable market, rivals are still eager to join the race. Bank …
Health care may be a real challenger to tech this year, a business that can actually grow faster than most of tech and has the possibility of a comeback from …
CNBC’s Jim Cramer on Friday told investors what to watch for on Wall Street next week, highlighting JPMorgan‘s market-moving health-care conference in San Francisco. Taking place from Monday to Thursday, …
For many struggling with obesity, new medications have been “a gift,” as Oprah Winfrey recently described it in declaring she was “done with the shaming.” Investors in drug manufacturers Novo …
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to …
One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat. What this means for patients over the long …
The impact of new weight loss treatments is being felt well beyond the health-care industry . Analysts used the ritual of quarterly earnings calls to probe companies on whether their …